In the past couple of years, the united kingdom has witnessed a revolution in healthcare excess weight‑loss treatment options — through the introduction of semaglutide (Wegovy®) to the expanding acceptance of tirzepatide (Mounjaro®). Now, another identify is drawing interest in both medical and g